Medicines for rare diseases accounted for 41% of new FDA-approved drugs in 2016. However, developing new treatments for orphan indications is hugely challenging.
Two of the greatest difficulties consist of finding and recruiting enough subjects to support statistically valid clinical trials and properly and ethically caring for trial patients suffering the quality-of-life (QoL) issues these diseases engender. In this whitepaper, Challenging Conventional Patient Recruitment and Care Strategies for Rare Disease Studies, Tom Ruane, Senior Director, Patient Recruitment PAREXEL discusses how to challenge conventional patient recruitment methods and care strategies to successfully recruit patients for these important studies.
Download this whitepaper for insight on:
-
How conventions can get in the way
-
Patient-first trial design
-
Leveraging technology for the benefit of patients and clinicians